HOOKIPA Pharma to Participate in Upcoming SVB Leerink Global Healthcare Conference

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the virtual SVB Leerink Global Healthcare Conference on February 25, 2021, with a fireside discussion scheduled for 9:20 AM ET. This event will be accessible via a live audio webcast on HOOKIPA's website, alongside an archived replay available for 30 days post-event. HOOKIPA is advancing a new class of immunotherapeutics through its proprietary arenavirus platform, focusing on treatments for cancers and infectious diseases, including a Phase 1/2 trial for HPV-positive cancers and a Phase 2 trial for a cytomegalovirus vaccine.

NEW YORK and VIENNA, Austria, Feb. 16, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in the upcoming virtual SVB Leerink Global Healthcare Conference:

• Fireside Discussion: Thursday, February 25, 2021 at 9:20 AM ET

The live audio webcast of the presentation will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event.

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.  HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, are designed induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, HOOKIPA’s replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. 

HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens, and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.  

HOOKIPA’s non-replicating prophylactic cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections. 

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:
Media		Investors
Nina Waibel		Matt Beck
Senior Director - Communications		Executive Director - Investor Relations
nina.waibel@hookipapharma.com		matthew.beck@hookipapharma.com

FAQ

What is HOOKIPA Pharma's participation in the SVB Leerink Global Healthcare Conference?

HOOKIPA Pharma will participate in the SVB Leerink Global Healthcare Conference on February 25, 2021, with a fireside discussion at 9:20 AM ET.

Where can I watch HOOKIPA's presentation at the SVB Leerink Conference?

The presentation will be available through a live audio webcast on HOOKIPA's website in the Investors & Media section.

What are HOOKIPA Pharma's lead product candidates?

HOOKIPA's lead product candidates include HB-201 and HB-202, which are in development for Human Papilloma Virus 16-positive cancers.

What trials is HOOKIPA currently conducting?

HOOKIPA is conducting a Phase 1/2 trial for HPV-positive cancers and a Phase 2 trial for its cytomegalovirus vaccine candidate.

Is HOOKIPA collaborating on any infectious disease research?

Yes, HOOKIPA has a collaboration and licensing agreement with Gilead Sciences to research arenavirus-based functional cures for HIV and chronic Hepatitis B.